| Autor: |
Chandima Jeewandara, Inoka Sepali Aberathna, Laksiri Gomes, Pradeep Darshana Pushpakumara, Saubhagya Danasekara, Dinuka Guruge, Thushali Ranasinghe, Banuri Gunasekera, Achala Kamaladasa, Heshan Kuruppu, Gayasha Somathilake, Osanda Dissanayake, Nayanathara Gamalath, Dinithi Ekanayake, Jeewantha Jayamali, Deshni Jayathilaka, Anushika Mudunkotuwa, Michael Harvie, Thashmi Nimasha, Ruwan Wijayamuni, Lisa Schimanski, Pramila Rijal, Tiong K. Tan, Tao Dong, Alain Townsend, Graham S. Ogg, Gathsaurie Neelika Malavige |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Immunity, Inflammation and Disease, Vol 10, Iss 4, Pp n/a-n/a (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2050-4527 |
| DOI: |
10.1002/iid3.592 |
| Popis: |
Abstract Background To understand the kinetics of immune responses with different dosing gaps of the AZD1222 vaccine, we compared antibody and T cell responses in two cohorts with two different dosing gaps. Methods Antibodies to the SARS‐CoV‐2 virus were assessed in 297 individuals with a dosing gap of 12 weeks, sampled 12 weeks post second dose (cohort 1) and in 77 individuals with a median dosing gap of 21.4 weeks (cohort 2) sampled 6 weeks post second dose. ACE2‐blocking antibodies (ACE2‐blocking Abs), antibodies to the receptor‐binding domain (RBD) of variants of concern (VOC), and ex vivo T cell responses were assessed in a subcohort. Results All individuals (100%) had SARS‐CoV‐2‐specific total antibodies and 94.2% of cohort 1 and 97.1% of cohort 2 had ACE2‐blocking Abs. There was no difference in antibody titers or positivity rates in different age groups in both cohorts. The ACE2‐blocking Abs (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
